PubMed

FDA 规范和处方数字疗法：随着它们所监管的技术发展。

PMID：37139487 · 2023-04-17

A, n, t, h, o, n, y, , W, a, t, s, o, n, ;, , R, i, c, h, a, r, d, , C, h, a, p, m, a, n, ;, , G, i, g, i, , S, h, a, f, a, i, ;, , Y, u, r, i, , A, , M, a, r, i, c, i, c, h

期刊Frontiers in digital health

年份2023-04-17

PMID37139487

摘要

Technological progress in digital therapeutics-and, in particular prescription digital therapeutics (PDTs)-has outpaced the processes that the Food and Drug Administration (FDA) uses to regulate such products. Digital therapeutics have entered the health care ecosystem so rapidly that substantial misunderstandings exist about how they are evaluated and regulated by the FDA. This review briefly explains the relevant regulatory history of software as medical devices (SaMDs) and reviews the current

官方来源

在 PubMed 上查看 →

数据来自 PubMed / NCBI。有关全文和最新信息，请始终参阅官方记录。